Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SF-2 rgp120 and MN rgp120 HIV Vaccines in Healthy Adults
NCT00001031Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SF-2 gp120 and MN rgp120/HIV-1 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and Reactogenicity and Immunogenicity. Status: completed.
02
Drugs
SF-2 gp120MN rgp120/HIV-1
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001031.